Market Cap : 10.09 B | Enterprise Value : 8.48 B | PE Ratio : 16.79 | PB Ratio : 2.31 |
---|
NAS:UTHR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:UTHR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
United Therapeutics has the Profitability Rank of 8. It has a higher profitability and may stay that way.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %United Therapeutics's Operating Margin % for the quarter that ended in Jun. 2022 was 43.22%. As of today, United Therapeutics's Piotroski F-Score is 7.
For the Biotechnology subindustry, United Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, United Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
United Therapeutics has the Profitability Rank of 8. It has a higher profitability and may stay that way.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
United Therapeutics's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as:
Operating Margin % | = | Operating Income (Q: Jun. 2022 ) | / | Revenue (Q: Jun. 2022 ) |
= | 201.8 | / | 466.9 | |
= | 43.22 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
United Therapeutics has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of United Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Benkowitz Michael | officer: President and COO | C/O UNITED THERAPEUTICS CORP 1040 SPRING STREET SILVER SPRING MD 20910 |
Maxwell Linda | director | 1040 SPRING STREET SILVER SPRING NC 27709 |
Thompson Tommy G | director | 7711 CARONDELET ST. LOUIS MO 63105 |
Mesa Nilda | director | C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING MD 20910 |
Klein Katherine J | director | STEINBERG HALL-DIETRICH HALL 3620 LOCUST WALK PHILADELPHIA PA 19104 |
Giltner Richard | director | C/O UNITED THERAPEUTICS CORPORTION 1735 CONNECTICUT AVE. NW WASHINGTON DC 20009 |
Olian Judy D. | director | 2000 AVENUE OF THE STARS 12TH FL LOS ANGELES CA 90067 |
Edgemond James | officer: CFO and Treasurer | 1040 SPRING STREET SILVER SPRING MD 20910 |
Zaccardelli David | officer: EVP & Chief Operating Officer | 300 TRI STATE INTERNATIONAL SUITE 272 LINCOLNSHIRE IL 60069 |
Eli Lilly & Co | 10 percent owner | LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285 |
Ferrari John Maxim | officer: CFO & Treasurer | 1110 SPRING STREET SILVER SPRING MD 20910 |
Patusky Christopher | director | |
Hicks Henry Beecher Iii | director | C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910 |
Gray R Paul | director | C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910 |
Dwek Raymond | director |
From GuruFocus
Other Sources
By Zacks 2022-02-25
By Zacks 2021-10-20
By Zacks 2022-03-14
By Zacks 2022-02-16
By Zacks 2021-12-03
By Zacks 2021-11-03
By Zacks 2021-06-04
By tipranks.com 2022-03-19
By Zacks 2021-06-17
By Zacks 2022-02-25
By Zacks 2021-06-23